Tlando (testosterone) capsule

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines

NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx 1

Purpose
The purpose of this assignment is for the student to synthesize pharmacological knowledge (i.e., core drug
knowledge, core patient variables, and nursing implications) of pharmacotherapeutic agents into a useful
teaching and learning tool for nurses and patients.

Course outcomes: This assignment enables the student to meet the following course outcomes:

CO1 Apply the concepts of pharmacotherapeutics, pharmacokinetics, pharmacodynamics, and pharmacogenomics to

the use of specific medication classifications in specific health conditions and in consideration of medication

side/adverse effects, nursing implications, and medication teaching. (POs 1, 2, and 3)

CO2 Apply principles of health promotion, as well as illness and injury prevention, to promote safety and effectiveness

of commonly used pharmacologic therapy across the lifespan, taking into consideration sociocultural,

genetic/genomic, developmental, and gender implications. (POs 3 and 8)

CO3 Utilize the nursing process in understanding the effects of drug therapy on health outcomes across the lifespan

within the framework of a diverse population of individuals, families, and communities. (PO 4)

Due date: Your faculty member will inform you when this assignment is due . The Late Assignment Policy applies
to this assignment.

Total points possible: 100 points

Preparing the assignment

Follow these guidelines when completing this assignment. Speak with your faculty member if you have questions.
1. Choose a pharmacological agent that has been on the market less than 5 years.

2. Research the literature and obtain two to three resources for current, evidence-based information related to the
pharmacological agent.

3. Develop a teaching brochure and one page paper following these guidelines.
a. Brochure

• Key/Relevant Drug Information (30 points/30%)
o Drug Class
o Mechanism of Action
o Drug Administration and Dosage
o Drug Interactions
o Lab effects/interference
o Special Considerations
o Potential Side Effects/Adverse Effects/Toxicities

• Patient Education Considerations (35 points/35%)
o Nursing Management
o Patient Education Considerations
o Patient Assessment
o Side Effects/Adverse Effects/Toxicities
o Special considerations

• Visual Effects/Creativity (10 points/10%)
o Developed per the required standard
o Appropriate for the intended audience
o Flesch-Kincaid reading level seventh grade or lower
o Graphics enhance the purpose of the brochure
o Brochure is visually appealing

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines

NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx 2

b. One Page Paper (15 points/15%)
• Describes intended brochure audience
• Describes intended use of brochure
• Includes

o Name
o Date
o Class
o Reference page

c. APA Format (5 points/5%)
• Includes no more than 3 unique errors with APA format (current ed.)
• At least two (2) scholarly, primary sources from the last 5 years, excluding the textbook, are provided

d. Writing and Mechanics (5 points/5%)
• Clearly written
• Includes no more than three unique errors of grammar
• Includes no more than three unique errors in writing mechanics
• Paper is one page, excluding references and title page

For writing assistance, visit the Writing Center.

Please note that your instructor may provide you with additional assessments in any form to determine that you
fully understand the concepts learned in the review module.

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines

NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx 3

Grading Rubric: Criteria are met when the student’s application of knowledge demonstrates achievement of the outcomes for this assignment.
Assignment Section and

Required Criteria
(Points possible/% of total points available)

Highest Level of
Performance

High Level of
Performance

Satisfactory Level
of Performance

Unsatisfactory
Level of

Performance

Section not
present in

paper

Brochure: Relevant Drug Information
(30 points/30%)

30 points 26 points 23 points 22 points 0 points

Required criteria
1. Drug Class

2. Mechanism of Action

3. Drug Administration and Dosage

4. Drug Interactions

5. Lab effects/interference

6. Special Considerations

7. Potential Side Effects/Adverse Effects/Toxicities

Includes no fewer
than 7 requirements
for section.

Includes no fewer
than 6
requirements for
section.

Includes no fewer
than 5
requirements for
section.

Includes 1-4 criteria
for section.

No requirements
for this section
present

Brochure: Patient Education Considerations
(35 points/35%)

35 points 28 points 26 points 23 points 0 points

Required criteria
1. Nursing Management

2. Patient Education Considerations

3. Patient Assessment

4. Side Effects/Adverse Effects/Toxicities

5. Special Considerations

Includes no fewer
than 5 requirements
for section.

Includes no fewer
than 4
requirements for
section.

Includes no fewer
than 3 requirements
for section.

Includes 1-2
requirements for
section.

No requirements
for this section
present.

Brochure: Visual Effects/Creativity
(10 points/10%)

10 points 8 points 7 points 4 points 0 points

Required criteria
1. Developed per the required standard

2. Appropriate for the intended audience

3. Flesch-Kincaid reading level seventh grade or lower

4. Graphics enhance the purpose of the brochure

5. Brochure is visually appealing

Includes no fewer
than 5 requirements
for section.

Includes no fewer
than 4 requirements
for section.

Includes no fewer
than 3 requirements
for section.

Includes 1-2
requirements for
section.

No requirements
for this section
present.

One Page Paper
(15 points/15%)

15 points 12 points 11 points 8 points 0 points

Required criteria
1. Describes intended brochure audience

2. Describes intended use of brochure

3. Includes

Includes no fewer
than 6
requirements for
section.

Includes no fewer
than 5
requirements for
section.

Includes no fewer
than 4
requirements for
section.

Includes 1-3 criteria
for section.

No requirements
for this section
present.

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines

NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx 4

Assignment Section and
Required Criteria

(Points possible/% of total points available)

Highest Level of
Performance

High Level of
Performance

Satisfactory Level
of Performance

Unsatisfactory
Level of

Performance

Section not
present in

paper

o Name

o Date

o Class

o Reference page

APA Format
(5 points/5%)

5 points 2 points 0 points

Required criteria
1. Includes no more than 3 unique errors with APA

format (current ed.)

2. At least two (2) scholarly, primary sources from the
last 5 years, excluding the textbook, are provided

Includes 2 requirements for section. Includes 1
requirement for
section.

No requirements
for this section
present.

Writing Mechanics
(5 points/5%)

5 points
4 points 2 points 0 points

Required criteria
1. Clearly written

2. Includes no more than three unique errors of
grammar

3. Includes no more than three unique errors in
writing mechanics

4. Paper is 1 page, excluding title and reference pages

Includes no fewer than 4 requirements for
section.

Includes no fewer
than 3 requirements
for section.

Includes 1-2
requirements for
section.

No requirements
for this section
present.

Total Points Possible = 100 points

Drug Interactions

Dayvigo should not be taken with a strong or moderate CYP3A inducers as they could reduce its effectiveness. These include rifampin, carbamazepine, efavirenz, and etravirine.

Special Considerations

Special consideration should be given to patients with complex sleep behaviors such as sleep walking, patients with a compromised respiratory system, chronic depression, suicidal ideation, pregnancy, drug addiction and comorbid diagnosis

Potential Side Effects/Toxicities

Unusual drowsiness, generalized weakness and fatigue, sleep paralysis, somnambulism, allergic reactions, worsening depression or suicidal ideations.

Dayvigo

Nursing Indications

he nurse should ensure that the patient is well educated on the drug use, especially the dosage and the potential side effects.

The Nurse should also ensure patient safety by examining occupation,, sleep history and mental health of the patient fist.

Patient Assessment

The patient’s sleep disorder should be assessed as this drug can cause complex sleep disorders. The patient should also not be an operator of heavy machinery as the drug can cause drowsiness at work. The patient should not have a history of sleep paralysis of sleep walking as the drug can make them worse.

Special considerations.

Women who are pregnant should be given special consideration. The drug should not be prescribed to children. Drug addicts and people with liver impairment should be given special consideration too.

Side Effect management

The medication should be changed if serious side effects are experienced.

Regular users should undergo regular liver function tests to determine if it is being affected.

Patients who experience of exhibit signs of depression should cease using the drug.

The dosage should be at the minimum affective level to avoid overdose toxicity.

The medication should only be taken immediately before getting into bed.

The dosage and schedule given by the doctor in the prescription should always be strictly followed.

Patient Education

Patient should not be an addict and should not take alcohol.

Any episodes of sleep paralysis, muscle weakness or sleep activity should be reported promptly.

The patient can experience daytime sleepiness when using the drug, so caution should be taken to avoid causing accidents

Usage of he medication should be ceased immediately if once s the patient is pregnant.

Drug Description

Dayvigo is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg

It can be co-administered with a CYP3A inhibitor

Dayvigo treats insomnia by blocking the binding sites of the wake promoting neuropeptides Orexin A and Orexin B, thereby suppressing wake drive causing drowsiness.